US Stock Insider Trading | Standard BioTools Disclosed 3 Company Insider Transactions on March 2

K-LinePoet · 2026-03-13T01:33:03+00:00

Standard BioTools disclosed insider transactions in 2026, with directors Cox Troy and Casdin Eli each purchasing 57,300 shares and 53,000 shares respectively on February 26. The company focuses on life science research technology, dedicated to accelerating breakthroughs in human health.

K-LinePoet

2026-03-13 01:33:03

Abstract generation in progress

On March 2, 2026, Standard BioTools (LAB) disclosed three insider trading transactions. Director Cox Troy purchased 57,300 shares on February 26, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	>10% Shareholder	Casdin Eli	February 26, 2026	Buy	53,000	1.17	62,000
March 2, 2026	Director	Carey Thomas D., Cox Troy	February 26, 2026	Buy	108,500	1.17	127,000
February 24, 2026	Executive	Mackay Sean	February 23, 2026	Sell	19,700	1.15	22,600
February 24, 2026	Director	Egholm Michael	February 23, 2026	Sell	66,100	1.15	76,000
February 24, 2026	Executive	Kim Hanjoon Alex	February 23, 2026	Sell	12,700	1.15	14,700
December 4, 2025	>10% Shareholder	Casdin Partners Master Fund, L.P.	December 3, 2025	Buy	75,000	1.44	108,000
December 4, 2025	>10% Shareholder	Casdin Partners Master Fund, L.P.	December 4, 2025	Buy	150,000	1.45	217,000
December 2, 2025	>10% Shareholder	Casdin Partners Master Fund, L.P.	December 2, 2025	Buy	125,000	1.42	177,500
November 25, 2025	>10% Shareholder	Casdin Partners Master Fund, L.P.	November 25, 2025	Buy	7,550,000	1.30	9,838,400
November 24, 2025	>10% Shareholder	Casdin Partners Master Fund, L.P.	November 24, 2025	Buy	150,000	1.43	214,900

【Company Profile】

Standard BioTools Inc. was founded on May 19, 1999, in California. The company creates, manufactures, and sells innovative technologies and tools for life science research. Driven by a bold goal—to unlock tools that accelerate breakthroughs in human health—the company develops, manufactures, and sells technologies that help biomedical researchers find drugs faster and more effectively. Its tools utilize proprietary high-throughput cell analysis and microfluidic technologies to provide insights into health and disease, serving applications in proteomics and genomics.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes